AstraZeneca CEO Pascal Soriot stated the U.K.-listed company had numerous reasons to be in the U.S., including that it was “rapidly moving manufacturing” across the Atlantic.
Source
Related Articles
AstraZeneca CEO doubles down on U.S. amid reports of listing shift